DARE — Dare Bioscience Cashflow Statement
0.000.00%
Last trade - 00:00- $28.16m
- $17.69m
- $2.81m
Annual cashflow statement for Dare Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -14.3 | -27.4 | -38.7 | -30.9 | -30.2 |
| Depreciation | |||||
| Non-Cash Items | 0.26 | 0.58 | 1.18 | 2.14 | 2.61 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.677 | 1.54 | 8.73 | 10.7 | -11.3 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -13.3 | -25.2 | -28.8 | -18.1 | -38.9 |
| Capital Expenditures | 0 | -0.018 | -0.015 | -0.063 | -0.629 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 6.14 | 0 | — | — | — |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Cash from Investing Activities | 6.14 | -0.018 | -0.015 | -0.063 | -0.629 |
| Financing Cash Flow Items | — | — | — | — | 4.72 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 5.15 | 25.1 | 75.8 | 1.34 | 15.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2.03 | -0.111 | 47 | -17 | -23.9 |